Combination Therapy Shows Promise for PAH Treatment
(#1080799, Wednesday, October 26, 3:00 PM Eastern)
Current treatments for pulmonary arterial hypertension (PAH) often entail observing patient deterioration when using a single medication and seeing its effects before starting a second medication. Researchers from Calgary, AB, Canada conducted clinical trials on high-risk patients with a mean age of 60 years who had idiopathic and connective tissue disease-associated PAH. The researchers administered a first-line oral combination therapy of bosentan and sildenafil, which yielded improvements in 6-min walk test, symptoms, and blood flow and cardiac function parameters. This strategy appears to be relatively safe and well tolerated by the patients in this study. However, the magnitude and durability of clinical improvements along with the risks of early drug-induced liver damage remain unclear and warrant further study.
Catheter-Related Bloodstream Infections Significantly Decreased After Guideline Implementation
(#1108555, Tuesday, October 25, 3:00 PM Eastern)
Evidence-based guidelines have been shown to improve health-care outcomes. In 2006, a guideline called the Institute of Health Improvement Bundle was created to help hospitals reduce the rate of catheter-related bloodstream infection (CRBSI), the most frequently occurring nosocomial infection. Researchers from the Spinal Cord Injury Center (SCI) at the James A. Haley Veterans Hospital and the University of South Florida, both in Tampa, retrospectively reviewed the charts of 895 patients admitted
|Contact: Sue Roberts|
American College of Chest Physicians